GlassScriptPhysician profile
Wallace R Hodges
NPI 1841288016
$361.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $138 · 2021: $53.21 · 2022: $20.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.21 | 2021 | |
| Lilly USA, LLC | $50.45 | 2019-2022 | |
| Allergan, INC. | $49.98 | 2020 | |
| Merck Sharp & Dohme LLC | $36.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.47 | 2019-2020 | |
| Boston Scientific Corporation | $30.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $24.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.67 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.86 | 2019 | |
| Alfasigma USA, INC. | $13.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.90 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.82 | 2019 | |
| Glaxosmithkline, LLC. | $12.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.